StreetInsider.com News Articles

OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments

Thu, 30 Apr 2026 12:00:00 -0400

Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology)
Significant progress with OPM-201: independent validation of the compound’s potency and selectivity, and strategic support of $7 million from the Michael J. Fox Foundation
Strategic refocusing of R&D investments (-52% to €3.13 million) on priority assets and higher-value programs
Cash position of €2.11 million as of December 31, 2025
Continued implementation of the cost optimization and operational discipline plan, with €5.9 million in savings achieved during the fiscal year

DIJON, France--(BUSINESS WIRE)-- Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol:

OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments

Thu, 30 Apr 2026 12:00:00 -0400

Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology)
Significant progress with OPM-201: independent validation of the compound’s potency and selectivity, and strategic support of $7 million from the Michael J. Fox Foundation
Strategic refocusing of R&D investments (-52% to €3.13 million) on priority assets and higher-value programs
Cash position of €2.11 million as of December 31, 2025
Continued implementation of the cost optimization and operational discipline plan, with €5.9 million in savings achieved during the fiscal year

DIJON, France--(BUSINESS WIRE)-- Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol:

OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments

Thu, 30 Apr 2026 12:00:00 -0400

Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology)
Significant progress with OPM-201: independent validation of the compound’s potency and selectivity, and strategic support of $7 million from the Michael J. Fox Foundation
Strategic refocusing of R&D investments (-52% to €3.13 million) on priority assets and higher-value programs
Cash position of €2.11 million as of December 31, 2025
Continued implementation of the cost optimization and operational discipline plan, with €5.9 million in savings achieved during the fiscal year

DIJON, France--(BUSINESS WIRE)-- Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol:

OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments

Thu, 30 Apr 2026 12:00:00 -0400

Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology)
Significant progress with OPM-201: independent validation of the compound’s potency and selectivity, and strategic support of $7 million from the Michael J. Fox Foundation
Strategic refocusing of R&D investments (-52% to €3.13 million) on priority assets and higher-value programs
Cash position of €2.11 million as of December 31, 2025
Continued implementation of the cost optimization and operational discipline plan, with €5.9 million in savings achieved during the fiscal year

DIJON, France--(BUSINESS WIRE)-- Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol:

OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments

Thu, 30 Apr 2026 12:00:00 -0400

Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology)
Significant progress with OPM-201: independent validation of the compound’s potency and selectivity, and strategic support of $7 million from the Michael J. Fox Foundation
Strategic refocusing of R&D investments (-52% to €3.13 million) on priority assets and higher-value programs
Cash position of €2.11 million as of December 31, 2025
Continued implementation of the cost optimization and operational discipline plan, with €5.9 million in savings achieved during the fiscal year

DIJON, France--(BUSINESS WIRE)-- Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol:

OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments

Thu, 30 Apr 2026 12:00:00 -0400

Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology)
Significant progress with OPM-201: independent validation of the compound’s potency and selectivity, and strategic support of $7 million from the Michael J. Fox Foundation
Strategic refocusing of R&D investments (-52% to €3.13 million) on priority assets and higher-value programs
Cash position of €2.11 million as of December 31, 2025
Continued implementation of the cost optimization and operational discipline plan, with €5.9 million in savings achieved during the fiscal year

DIJON, France--(BUSINESS WIRE)-- Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol:

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Tue, 03 Mar 2026 12:30:00 -0400

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation

The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases

Thu, 08 Jan 2026 12:00:00 -0400

DIJON, France & STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.
Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells

Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics

Mon, 29 Dec 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended

Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics

Mon, 29 Dec 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended

Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics

Mon, 29 Dec 2025 12:00:00 -0400

DIJON, France--(BUSINESS WIRE)-- Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin® technology platform, jointly announce the termination of their collaboration agreement signed in May 2024.
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended